Scarica l'app Stockscreener
32.74
0.80%
0.26
Dopo l'orario di chiusura:
32.74
Precedente Chiudi:
$32.48
Aprire:
$32.02
Volume 24 ore:
694.02K
Relative Volume:
0.77
Capitalizzazione di mercato:
$2.88B
Reddito:
$218.71M
Utile/perdita netta:
$-113.70M
Rapporto P/E:
-25.12
EPS:
-1.3034
Flusso di cassa netto:
$-73.47M
1 W Prestazione:
+2.03%
1M Prestazione:
-0.91%
6M Prestazione:
+20.37%
1 anno Prestazione:
+100.24%
Intervallo 1D:
$31.91
$33.45
Intervallo di 1 settimana:
$30.00
$34.47
Portata 52W:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
32.74 | 2.88B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDYA PE Ratio & Valuation, Is IDYA Overvalued - intellectia.ai
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - finance.yahoo.com
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - finance.yahoo.com
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
IDEAYA Biosciences Achieves 119.91% Growth, Establishing It as a Multibagger in Biotechnology Sector - Markets Mojo
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Block Trades: Does IDEAYA Biosciences Inc have a competitive edge2026 Key Highlights & Advanced Technical Analysis Signals - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL - MarketBeat
Price-Driven Insight from (IDYA) for Rule-Based Strategy - Stock Traders Daily
IDEAYA begins combination trial of IDE849 and IDE161 cancer drugs By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma – Company Announcemen - Financial Times
IDEAYA Biosciences Opens Weak with 5.14% Gap Down Amid Market Concerns - Markets Mojo
Vanguard disaggregates holdings; affiliates to report separately (IDYA) - stocktitan.net
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Finviz
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Incyte (INCY) - The Globe and Mail
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness - simplywall.st
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay - Investing.com
Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - marketbeat.com
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - marketbeat.com
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data - Investing.com
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - Sahm
IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada
IDEAYA delays darovasertib trial results to mid-April - investing.com
Cancer trial readout nears as IDEAYA targets first-half April lock - Stock Titan
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill
(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart.com
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Finviz
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial - GuruFocus
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):